linjc16/ctgov huggingface dataset:
Upper GI Outcomes Following EMR

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the long-term outcomes of Endoscopic Resection (ER) of superficial lesions of the Upper Gastrointestinal Tract(UGIT)

Detailed Description
-----------------
Endoscopic resection (ER) of superficial lesions of the upper gastrointestinal tract is a safe and effective surgery-sparing modality in experienced hands. It is often curative of dysplastic lesions and is associated with minimal complications and high patient acceptance (1-5). Westmead Hospital has accumulated a significant amount of experience in the removal of such lesions; however, there is limited research to document the long term outcomes of patients undergoing endoscopic resection.The purpose of this study is to evaluate the long-term outcomes of ER of superficial lesions of the UGIT.

Official Title
-----------------
Outcomes of Endoscopic Resection in the Upper Gastrointestinal Tract

Conditions
-----------------
Adenoma, Villous

Intervention / Treatment
-----------------
* Procedure: Endoscopic Mucosal Resection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: UGIT lesion > 10mm Lesion limited to the mucosal and/or submucosal layer (T1 lesion) Aged 18 years or older Exclusion Criteria: Lesion less than 10mm Gastric lesion involves the muscularis propria (T2 lesion) on other staging modalities such as endoscopic ultrasonography (EUS) Aged younger than 18 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Endoscopic Mucosal Resection<br>Patients who are referred for Endoscopic Mucosal Resection of Upper Gastrointestinal Lesions will be included in this cohort. | Procedure: Endoscopic Mucosal Resection<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Observed procedural data | Number of Participants with Adverse Events as a Measure of Safety and Tolerability Outcomes | 14 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Analysis of the costs of this procedure compared to previous treatments | Perform cost-utility analyses comparing different treatment approaches for UGIT lesions | 14 days |
Prophylactic Amiodarone for Shockable Cardiac Arrest

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to determine whether the prophylactic amiodarone can prevent re-arrest with ventricular shockable rhythm in patients who treated with targeted temperature management after return of spontaneous circulation from cardiac arrest which had been shockable rhythm during CPR.

Detailed Description
-----------------
Patients with cardiac arrest are in high risk of re-arrest during post cardiac arrest care due to vulnerable heart state electrically and hemodynamically. Especially if patients who had experienced shockable rhythms such as ventricular fibrillation or pulseless ventricular tachycardia during CPR, then they are at high risk of developing shockable re-arrest. However until now there has not been any evidence of prophylactic anti arrhythmic drug effect during post cardiac arrest care. Amiodarone is class III anti arrhythmic drug which has been used for conversion of ventricular arrhythmia during CPR. In this study we want to determine whether the prophylactic amiodarone can prevent re-arrest with ventricular shockable rhythm or not.

Official Title
-----------------
Prophylactic Amiodarone for Shockable Cardiac Arrest During Targeted Post Cardiac Arrest Care: Multi-center, Open Labelled Randomized Controlled Trial

Conditions
-----------------
Cardiac Arrest, Ventricular Arrythmia

Intervention / Treatment
-----------------
* Drug: Amiodarone Injection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Non traumatic cardiac arrest patients who had VF or pVT during CPR in ER Exclusion Criteria: age < 18 yr pregnancy non cardiac caused arrest such as hanging previous amiodarone continuous infusion before radomization sustained ventricular arrhythmia recurrence after ROSC extracorporeal membrane oxygenation contra indication for amiodarone disagree with this research

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Prophylactic amiodarone<br> | Drug: Amiodarone Injection<br>* Amiodarone continuous infusion during 24 hours from return of spontaneous circulation.<br>|
| No Intervention: Conventional management<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with re-arrest by shockable rhythm | No recurrence of ventricular fibrillation or pulseless ventricular tachycardia | 5 days from return of spontaneous circulation |
Role of LIDOCAINE IN Pediatric Cochlear Implant Surgery

Study Overview
=================
Brief Summary
-----------------
The stapedius reflex protects the ear from the loud noise. The measurement of the intraoperative electrically evoked stapedial reflex threshold (ESRT) during pediatric cochlear implants (CIs) is used to confirm that the implant is functioning correctly and determine the maximum comfortable level . Total intravenous anesthesia (TIVA) with propofol and remifentanil is frequently used for pediatric CIs as it does not suppress the ESRT. However, high doses of remifentanil exacerbates postoperative pain and increased opioid consumption.

Detailed Description
-----------------
Total intravenous anesthesia (TIVA) with propofol and remifentanil is frequently used for pediatric CIs as it does not suppress the ESRT. However, high doses of remifentanil exacerbates postoperative pain and increased opioid consumption.

Official Title
-----------------
Intravenous Lidocaine Reduces Remifentanil and Propofol Requirements Without Altering the Electrical Stapedial Reflex Threshold in Pediatric Cochlear Implants

Conditions
-----------------
Anesthesia

Intervention / Treatment
-----------------
* Drug: Lidocaine
* Other: Na CL 0.9%


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA I and II children Exclusion Criteria: uncontrolled hypertension, diabetes mellitus, liver disease, kidney disease, heart disease, allergy to lidocaine

Ages Eligible for Study
-----------------
Minimum Age: 6 Months
Maximum Age: 6 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Liocaine<br>Group Lid | Drug: Lidocaine<br>* Before induction of anesthesia; children in group LID received an iv bolus dose of LIDOCAINE 1 mg/kg over 5 minutes followed by 1 mg Kg-1 h-1 ivi until the start of skin closure.<br>* Other names: Xylocaine;|
| Active Comparator: Na CL 0.9%<br>group C | Other: Na CL 0.9%<br>* Before induction of anesthesia; children in group C equivalent volumes of Na Cl 0.9% over the same period instead of LIDOCAINE.<br>* Other names: isotonic saline solution;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Remifentanil consumption | microgram per kilogram | at the end of the surgey | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ESRT responses | the surgeon assessed ESRT response at the basal, middle, and apical areas of the electrode array by visual monitoring of the stapedius muscle using direct | After insertion of the electrode and after reversal of any residual muscle relaxant (TOF response > 0.9), |
Use of Fluticasone Propionate/Salmeterol Combination Post Emergency Department Visit

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to compare readmission to the emergency department for asthma in asthma patients who receive treatment with fluticasone propionate and salmeterol oral inhaler after an initial emergency department visit using a retrospective observational cohort study design.

Official Title
-----------------
Use of Fluticasone Propionate/Salmeterol Combination Post Emergency Department Visit

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Drug: Fluticasone propionate/salmeterol combination ED MD
* Drug: Fluticasone propionate/salmeterol combination OP MD


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects with asthma as determined by ICD-9 codes and asthma drug use at least 12 years of age discharged from an initial Emergency Department visit within 12 months Exclusion Criteria: Subjects with COPD or treatment for COPD

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Fluticasone propionate/salmeterol combination ED MD<br>Asthma subjects discharged from an institution after treatment for severe asthma exacerbation that receive fluticasone propionate/salmeterol combination from the ED physician | Drug: Fluticasone propionate/salmeterol combination ED MD<br>* Receipt of fluticasone propionate/salmeterol combination from the ED physician<br>|
| Fluticasone propionate/salmeterol combination OP MD<br>Asthma subjects discharged from an institution after treatment for severe asthma exacerbation that receive fluticasone propionate/salmeterol combination from the OP physician | Drug: Fluticasone propionate/salmeterol combination OP MD<br>* Receipt of fluticasone propionate/salmeterol combination from the OP physician<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants With an Asthma-related Event Occurring Between 1 and 6 Months Following the Index Event | A subsequent asthma-related inpatient (IP) visit or emergency department (ED) visit were defined as visits within 6 months of the index event. The index event was defined as an asthma-related hospitalization or ED visit occuring between 2004 and 2008. | Data were collected during a 4-year period from January 1, 2004 to December 31, 2008. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
fluticasone/propionate salmeterol combination, hospitalization, emergency department, asthma
Sedative and Hypnotic Effects Induced by EA

Study Overview
=================
Brief Summary
-----------------
Insomnia is a common clinical disease.The serious patients could not sleep all night, often accompanied by headache, dizziness, forgetfulness and so on. All of these increase the mental burden of insomnia patients and seriously affected the normal work and quality of life of patients. Modern medical treatment to treat insomnia is using sedative and hypnotic drugs, mainly benzodiazepine, zopiclone. But long-term use of these drugs can induce the adverse reactions, including resistance, dependence and addiction. Many articles indicate that electroacupuncture can effectively improve insomnia, play the role of sedative and hypnotic effect and avoid many adverse reactions and side effects. Then there are no more objective indicators to affirm that which part of brain takes place the appropriate changes when electroacupuncture induces the sedative effect. So we designed this experiment.

Official Title
-----------------
EA Induces Sedative and Hypnotic Effects by Detecting BIS Value and MRI.

Conditions
-----------------
Bypass Complications

Intervention / Treatment
-----------------
* Procedure: Electroacupuncture


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must be able to go with EA Can not have any disease Exclusion Criteria: Overworked recently

Ages Eligible for Study
-----------------
Minimum Age: 24 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Electroacupuncture preconditioning<br> | Procedure: Electroacupuncture<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| BIS value | The primary outcome is assessing whether BIS value reduce during electroacupuncture stimulation. | 30 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Electroacupuncture, Sedation
Assessment of International Normalized Ratio (INR) Prolongation in Patients Treated Simultaneously With Warfarin and Cephalosporins

Study Overview
=================
Brief Summary
-----------------
Many drug interactions with Warfarin are well documented in the literature, including interactions with a variety of antibiotics. However,in mamy cases it is difficult to predict when the interaction remains theoretical and when it becomes clinically significant and will be reflected in the individual patient. This study's aim is to identify and characterize related conditions (including comorbidities, laboratory test results and other parameters related to the patient)that might be predictors for drug interactions turning from theoretical to clinically significant.

Official Title
-----------------
Assessment of INR Prolongation in Patients Treated Simultaneously With Warfarin and Antibiotics From the Cephalosporins Family,Observational Retrospective Study.

Conditions
-----------------
Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients aged 18 and over Patients treated with a combination of Warfarin and Cephalosporins Patients who were hospitalized in the department of internal medicine Patients who were treated with Warfarin without Cefalosporins Exclusion Criteria: Patients on Warfarin who did not actually receive the drug during their hospitalization Patients whose medical records were not accessible or didn't contain full data

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reasons for INR prolongation in patients who were treated with the combination of Warfarin and Cephalosporins |  | Participants will be followed for the duration of thei hospital stay, an expected average of 7 days |
The Effect of Circadian Rhythms on Norctrend Index in Anesthesia

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether the Circadian Rhythms effects on the Norctrend Index in Anesthesia.

Detailed Description
-----------------
It has been reported that circadian rhythm has many aspects of influence on human body. But little is knew about the circadian rhythm affect on Narcotrend index (made in Germany) in total intravenous anesthesia .The investigators' study is to find the relationship between them.

Conditions
-----------------
Patients Needed Surgery and Anesthesia, Except on the Head or Facial Surgery

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: American Society of Anesthesiologists（ASA） Ⅰ - Ⅱ; ability to compliance the research plan; volunteered and signed for the study ; receive surgery and general anesthesia Exclusion Criteria: ASA>Ⅱ; Head or facial surgery can't collaborate;

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| A：day<br>the patients who receive surgery and anesthesia during 8:00 am to 6:00 pm | |
| B：night<br>the patients who receive surgery and anesthesia during 10:00 pm to 5:00 am next day | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| narcotrend index | the narcotrend index we recorded during the surgery and anesthesia in appropriate depth of anesthesia | during operation time |
Vascular and Metabolic Effects of Rosuvastatin

Study Overview
=================
Brief Summary
-----------------
The investigators hypothesize that rosuvastatin does-dependently worsens insulin sensitivity.

Conditions
-----------------
Hypercholesterolemia

Intervention / Treatment
-----------------
* Drug: placebo
* Drug: rosuvastatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: hypercholesterolemia Exclusion Criteria: overt liver disease, chronic renal failure, hypothyroidism, myopathy, uncontrolled diabetes (HbA1c > 9%), severe hypertension, stroke, acute coronary events, coronary revascularization within the preceding 3 months, or alcohol abuse

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: placebo<br>placebo | Drug: placebo<br> <br> |
| Active Comparator: rosuvastatin 5<br>rosuvastatin 5 mg | Drug: rosuvastatin<br> <br> |
| Active Comparator: rosuvastatin 10<br>rosuvastatin 10 mg | Drug: rosuvastatin<br> <br> |
| Active Comparator: rosuvastatin 20<br>rosuvastatin 20 mg | Drug: rosuvastatin<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| flow-mediated dilation |  | 8 weeks of treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| insulin resistance |  | 8 weeks of treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
insulin resistance
NAFLD Study: US vs Liver Biopsy

Study Overview
=================
Brief Summary
-----------------
Evaluate the diagnostic accuracy of the new ultrasound software vs hepatic histology, the current reference standard for the diagnosis of NAFLD and NASH in 20 obese patients (BMI> 30) candidates for laparoscopic bariatric surgery and / or cholecystectomy

Official Title
-----------------
Diagnostic Accuracy in a New Ultrasound Software Compared to Histology for Non Alcoholic Fatty Liver Disease (NAFLD) and Non Alcoholic Steato Hepatitis (NASH) in Morbidly Obese Individuals Undergoing Bariatic Surgery and/or Cholecystectomy

Conditions
-----------------
Non-Alcoholic Fatty Liver Disease

Intervention / Treatment
-----------------
* Diagnostic Test: shear waves elastography; liver biopsy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who are candidates for bariatric surgery between the ages of 18 and 65, BMI> 40 kg / m2, in the absence of any other comorbidity BMI> 35 kg / m2, in the presence of comorbidities among those classically considered to be associated with obesity ICM> 30 kg / m2, in the presence of T2DM not in glycometabolic compensation Patients who are candidates for laparoscopic cholecystectomy for symptomatic calculi with BMI> 30 Exclusion Criteria: Age ≤ 18 or ≥ 65 Any concurrent surgical procedure except cholecystectomy and hiatal hernia repair Conversion into laparotomy surgery Post-operative complications requiring new surgical treatment Patient not compliant in the follow-up

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: liver biopsy<br> | Diagnostic Test: shear waves elastography; liver biopsy<br>* Diagnostic accuracy in a new ultrasound software compared to histology for Non Alcoholic Fatty liver disease (NAFLD) and Non Alcoholic Steato Hepatitis (NASH)<br>|
| Other: ATI<br> | Diagnostic Test: shear waves elastography; liver biopsy<br>* Diagnostic accuracy in a new ultrasound software compared to histology for Non Alcoholic Fatty liver disease (NAFLD) and Non Alcoholic Steato Hepatitis (NASH)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| diagnostic accurancy of ATI in obese patients | a new ultrasound software compared with liver biopsy in obese patients. | 6 months |